Development of liposomal systems of finasteride for topical applications: Design, characterization, and in vitro evaluation

Pharmaceutical Development and Technology

Volumn 12, Issue 6, 2007, Pages 591-601

  Kumar, Rajiv ^a   Singh, Bhupinder ^a   Bakshi, Gautam ^a   Katare, Om Prakash ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Dermatological disorders; Drug delivery; Permeation; Phospholipids; Skin; Transepidermal; Vesicles

Indexed keywords

CHOLESTEROL; DICETYL PHOSPHATE; FINASTERIDE; PHOSPHATIDYLCHOLINE;

ARTICLE; DRUG DESIGN; DRUG SCREENING; DRUG STABILITY; GEL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MALE; NONHUMAN; PRIORITY JOURNAL; SKIN PERMEABILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHOLESTEROL; DRUG COMPOUNDING; DRUG STABILITY; ENZYME INHIBITORS; FINASTERIDE; LIPOSOMES; MICE; PERMEABILITY; PHOSPHOLIPIDS; SKIN;

EID: 37549007228     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450701481181     Document Type: Article

References (53)

1. Stoner, E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J. Steroid Biochem. Mol. Biol. 1990, 37, 375-378.
2. Xu, Y.; Dalrymple, S.L.; Becker, R.E.; Denmeade, S.R.; Issacs, J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin. Cancer Res. 2006, 12, 4072-4079.
3. Canby-Hagino, E.D.; Brand, T.C.; Hernandez, J.; Thompson, I.M. Chemoprevention of prostate cancer with finasteride. Expert Opin. Pharmacother. 2006, 7, 899-905.
4. Teillac, P.; Abrahamsson, P.A. The role of Finasteride in the management of BPH and in the prevention of prostate cancer. Eur. Urol. Suppl. 2006, 5, 627.
5. Thompson, M.; Goodman, P.J.; Tangen, C.M.; Lucia, M.S.; Miller, G.J.; Ford, L.G.; Lieber M.M.; Cespedes, R.D.; Atkins, J.N.; Lippman, S.M.; . Carlin, S.M; Ryan, A.; Szczepanek, C.M.; Crowley, J.J.; Coltman Jr., C.A. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003, 349, 215-224.
6. Geller, J. Five-year follows up of patients with benign prostatic hyperplasia treated with finasteride. Eur. Urol. 1995, 27, 267-273.
7. Gormley, G.J.; Stoner, E.; Bruskewitz, R.C.; Imperato-McGinley, J.; Walsh, P.C.; McConnell, J.D.; Andriole, G.L.; Geller, J.; Bracken, B.R.; Tenover, J.S. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 1992, 327, 1185-1191.
8. Chen, W.; Zouboulis, C.C.; Orfanos, C.E. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996, 193, 177-184.
9. Van Neste, D. Natural scalp hair regression in preclinical stages of male androgenetic alopecia and its reversal by finasteride. Skin Pharmacol. Physiol. 2006, 19, 168-176.
10. Moghetti, M.; Castello, R.; Magnani, C.M.; Tosi, F.; Negri, C.; Armanini, D.; Bellotti, G.; Muggeo, M. Clinical and hormonal effects of 5 alpha-reducatse inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metab. 1994, 79, 115-1121.
11. Meidan, V.M.; Touitou E. Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. Drugs 2001, 61, 53-69.
12. Wong, L.; Morris, R.S.; Chang, L.; Spahn, M.A.; Stanczy, F.Z.; Lobo, R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab. 1995, 80, 233-238.
13. Shapiro, J.; Kaufman, K.D. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J. Invest. Dermatol. Symp. Proc. 2003, 8, 20-23.
14. Mellin, T.N.; Busch, R.D.; Rasmusson, G.H. Azasteroids as inhibitors of testosterone 5 alpha-reductase in mammalian skin. J. Steroid Biochem. Mol. Biol. 1993, 44, 121-131.
15. Diani, A.R.; Mulholland, M.J.; Shull, K. Hair growth effects of oral administration of finasteride, a steroid 5-alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stump tail macaque. J. Clin. Endocrinol. Metab. 1992, 74, 345-350.
16. Propecia® (Finasteride): Information for health care professionals. Merck & Co. Inc. Whitehouse Station, NJ 08889, USA. Available at http://www.propecia.com/finasteride/propecia/consumer/index.jsp. Accessed 10 Septemeber 2006
17. Chen, C.; Puy, L.A.; Simrad, J.; Li., X.; Singh, S.M.; Labrie, F. Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzymatic activity. J. Invest. Dermatol. 1995, 105, 678-682.
18. Choudhry, R.; Hodgin, M.B.; Vander Kwast, T.H.; Brinkmann, A.O.; Boersma, W.J. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous gland and sweat glands. J. Endocrinol. 1992, 133, 467-475.
19. Price, V.H.; Menefee, E.; Sanchez, M.; Kaufman, K.D. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): Three- and 4-year results. J. Am. Acad. Dermatol. 2006, 55, 71-74.
20. Price, V.H.; Roberts, J.L.; Hordinsky M.; Olsen, E.A.; Savin, R.; Bergfeld, W.; Fiedler, V.; Lucky, A.; Whiting, D.A.; Pappas, F.; Culbertson, J.; Kotey, P.; Meehan, A.; Waldstreicher, J. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J. Am. Acad. Dermatol. 2000, 43, 768-776.
21. Green, L. Gynacomastia and breast cancer during finasteride therapy. N. Engl. J. Med. 1996, 335, 823.
22. Steiner, J.F. Clinical phamacokinetics and pharmacodynamics of finasteride. Clin. Phamacokinet. 1996, 30, 16-27.
23. Hadgraft, J. Passive enhancement strategies in topical and transdermal drug delivery. Int. J. Pharm. 1999, 184, 1-6.
24. Cevc, G. Drug delivery across the skin. Expert. Opin. Investig. Drugs 1997, 6, 1887-1937.
25. Hadgraft, J. Recent developments in topical and transdermal delivery. Eur. J. Drug. Metab. Pharmacokinet. 1996, 21, 165-173.
26. Goyal, P.; Goyal, K.; Kumar, V.; Singh, A.; Katare, O.P.; Mishra, D.N. Liposomal drug delivery systems - Clinical applications. Acta Pharm. 2005, 55, 1-25.
27. Schmid, M.H.; Korting, H. C. Liposomes: A drug carrier system for topical treatment in dermatology. Crit. Rev. Ther. Drug Carrier Syst. 1994, 11, 97-118.
28. Fahr, A.; Mueller, R. Cyclosporin invasomes as topical drug delivery systems for the therapy of immune system related skin diseases. European Patent Application 2002, 2054 20020208.
29. Yarosh, D.B. Liposomes in investigative dermatology. Photodermatol. Photoimmunol. Photomed. 2001, 17, 203-212.
30. Singh, B.; Mehta, G.; Kumar, R.; Bhatia, A.; Ahuja, N.; Katare, O.P. Design, development and optimization of nimesulide-loaded liposomal systems for topical application. Curr. Drug Deliv. 2005, 2, 143-153.
31. Bhatia, A.; Kumar, R.; Katare, O.P. Tamoxifen entrapped topical liposomes: Development, characterization and in-vitro evaluation. J. Pharm. Pharm. Sci. 2004, 7, 252-259.
32. Agarwal, R.; Katare, O.P.; Vyas, S.P. Preparation and in-vitro evaluation of liposomal/niosomal delivery systems of antipsoriatic drug dithranol. Int. J. Pharm. 2001, 228, 43-52.
33. Bouwstra, J.A.; Honeywell-Nguyen, P.L.; Gooris, G.S.; Ponec, M. Structure of the skin barrier and its modulation by vesicular formulations. Prog. Lipid Res. 2003, 42, 1-36.
34. Tabbakhian, M.; Tavakoli, N.; Jaafari, M.R.; Daneshamouz, S. Enhancement of follicular delivery of finasteride by liposomes and niosomes. 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int. J. Pharm. 2006, 323, 1-10.
35. Manosroi, L.K.; Manosroi, J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int. J. Pharm. 2004, 270, 279-286.
36. Bangham, D.; Standish, M.M.; Watkins, J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13, 238-252.
37. Dipali, S.R.; Kulkarni, S.B.; Betagiri, G.V. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods. J. Pharm. Pharmacol. 1996, 48, 1112-1115.
38. New, R.R. C. Liposomes: A Practical Approach; IRL Press: Oxford, 1990.
39. Gupta, P.N.; Mishra, V.; Rawat, A.; Dubey, P.; Mahor, S.; Jain, S.; Chatterji, D. P.; Vyas, S.P. Non-invasive vaccine delivery in transferosomes, niosomes and liposomes: a comparative study. Int. J. Pharm. 2005, 293, 73-82.
40. Trotta, M.; Peira, E.; Carlotti, M.E.; Gallarate, M. Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. 2004, 270, 119-125.
41. Manosroi, A.; Podjanasoonthon, K.; Manosroi, J. Development of novel topical tranexamic acid liposome formulation. Int. J. Pharm. 2002, 235, 61-70.
42. Heurtault, B.; Saulnier, P.; Pech, B.; Proust, J.E.; Jean-Pierre, B. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003, 24, 4283-4300.
43. Carafa, M.; Santucci, E.; Lucania, G. Lidocaine-loaded non-ionic surfactant vesicles: Characterization and in vitro permeation studies. Int. J. Pharm. 2002, 231, 21-32.
44. Valenta C.; Wanka, M.; Heidlas, J. Evaluation of a novel soya-lecithin formulation for dermal use containing ketoprofen as a model drug. J. Control. Release 2000, 63, 165-173.
45. Ogiso, T.; Niinaka, N.; Iwaki, M. Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J. Pharm. Sci. 1996, 85, 57-64.
46. Dreher, F.; Walde, P.; Walther, P.; Wehrli, E. Interaction of a lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J. Control. Release 1997, 45, 131-140.
47. Walde, P.; Giuliani, A.M.; Boicelli, C.A.; Luisi, P.L. Phospholipid-based reverse micelles. Chem. Phys. Lipids 1990, 53, 265-288.
48. Fahr, A.; Blume, G.; Verma, S.; Verma, D.D. Particle size of liposomes influences dermal delivery of substances into skin. Int. J. Pharm. 2003, 258, 141-151.
49. Yu, H.Y.; Liao, H.M. Triamcinolone permeation from different liposome formulations through rat skin in-vitro. Int. J. Pharm. 1996, 127, 1-7.
50. Abraham, W.; Downing, D.T. Interaction between corneocytes and stratum corneum lipid liposomes in vitro. Biochim. Biophys. Acta 1990, 1021, 119-125.
51. Plessis, J. du.; Ramachandran, C.; Weiner, N.; Muller, D.G. The influence of particle size of liposomes on the deposition of drug into skin. 1994, 103, 277-282.
52. Yarosh, D.B. Liposomes in investigative dermatology. Photodermatol. Photoimmunol. Photomed. 2001, 17, 203-212.
53. Gabrijelcic, V.; Sentjure, M. Influence of hydrogels on liposome stability and on the transport of liposome entrapped substances into the skin. Int. J. Pharm. 1995, 118, 207-212.